Exclusive-Kimberly-Clark readies asset sales in bid for EU nod for Kenvue deal, sources say

Kimberly-Clark is preparing potential concessions to address EU antitrust concerns over its $40 billion acquisition of Kenvue, with the European Commission expected to formally outline concerns this week. The companies must decide whether to offer remedies before the preliminary EU review ends September 29 or face a four-month in-depth investigation. Australia already cleared the transaction subject to divestiture of Kenvue's Carefree and Stayfree brands, while South Africa granted conditional approval.

Analysis

The key valuation variable is no longer headline regulatory approval but remedy scope. The Australia precedent suggests localized brand divestitures can preserve the transaction’s strategic logic, but an EU package that reaches higher-margin personal-care franchises would reduce both revenue synergies and the multiple Kimberly-Clark can justify paying. A Phase II referral would likely create a 4-6 month extension, raising financing carry and exposing the deal to a weaker consumer-demand backdrop rather than necessarily signaling outright prohibition.

Near term, KMB should bear more of a delay/remedy penalty because its equity must absorb lost synergies, integration uncertainty and any incremental leverage; KVUE remains exposed to a larger discontinuation gap if remedies become economically unacceptable. The more consequential 6-18 month risk is that divestitures create scaled regional challengers in feminine care and skin health, potentially benefiting private-label retailers and competitors such as Edgewell Personal Care (EPC) in promotional shelf-space negotiations. Conversely, a narrowly targeted EU remedy could remove the principal overhang and force merger-arbitrage covering in KVUE.

Consensus may be treating any formal EU objections as a binary negative. Preliminary objections are often a negotiating step, and the prior conditional clearances imply the companies have a credible remedy playbook. The trade is therefore event-driven rather than a fundamental consumer-staples call: approval with modest remedies is positive for the deal spread, while an inability to submit remedies before the preliminary-review deadline materially increases the probability of a prolonged process and downside for both legs.

Key Decisions for Investors

• Run a small, hedged merger-arbitrage position only after confirming the consideration mix and live KMB/KVUE implied spread: long KVUE and short the exact KMB share-equivalent consideration. Target a 1-3 month catalyst around remedy submission/Phase I outcome; do not initiate if the annualized spread already discounts a Phase II process.
• If the Commission opens Phase II or remedy language includes core European skin-health or feminine-care brands, reduce KVUE exposure and tactically short KMB for 1-3 months. The thesis is synergy/financing multiple compression, not a deal break; cover on a quantified remedy package demonstrating limited EBITDA leakage.
• Maintain KMB as the preferred downside hedge against a protracted process rather than using broad staples ETFs. Falsify the bearish KMB leg if management reaffirms deal synergies and leverage targets after remedy disclosure with divestitures limited to immaterial local brands.
• Watch-item: assess KMB credit spreads, committed financing terms and the implied deal spread daily into September 29. A widening KMB credit spread alongside a widening KVUE discount would indicate financing risk is replacing pure antitrust risk and would argue against adding to the long-KVUE leg.